CalciMedica, Inc. (CALC): auditor change — CalciMedica restates FY2022 financials due to errors in convertible note and warrant valuation

CalciMedica, Inc.

Board concluded Dec 31, 2022 financial statements should no longer be relied upon.
Errors in valuation of convertible promissory notes and warrant liability; models did not consider merger conversion formula.
Restatement expected to decrease carrying value of notes and warrant liability, reduce net loss and net loss per share.
Company plans to file an amended report to reflect corrections; subject to completion of Ernst & Young audit.
Previously furnished/filed reports describing financial results from Original Report should no longer be relied upon.

item 4.02

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

CalciMedica, Inc. reported that prior financial statements should not be relied upon.

Action: non reliance
Auditor: Ernst & Young LLP

Exact text from the filing

concluded that each of (i) the Company’s financial statements as of and for the year ended December 31, 2022, as included in Exhibit 99.1 of the Company’s Form 8-K/A filed on April 4, 2023 (the “Original Report”) with the Securities and Exchange Commission (the “SEC) and (ii) the unaudited pro forma combined financial statements as of and for the year ended December 31, 2022, as included in Exhibit 99.2 of the Original Report (collectively, the “Financial Statements”), should be restated to correct for errors in the valuation of the convertible promissory notes and warrant liability as of December 31, 2022 and accordingly should no longer be relied upon

View on SEC.gov

46 auditor changes filed in the last 30 days. Browse all auditor changes →

CalciMedica, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-143456

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.